Introduction
The objectives of this article are firstly to review the function and clinical relevance of p-glycoprotein (pgp) in AML and secondly to review the current status of trials using pgp modulation and discuss why these have shown apparently conflicting results. Finally, we wish to discuss alternative strategies for overcoming drug resistance in AML.
The function and clinical relevance of pgp in AML P-glycoprotein (pgp), the product of the MDR1 gene, is a 170 kDa ATP-binding cassette (ABC) membrane transporter. (The gene is now also known as ABCB1 in the ABC transporter nomenclature.)
Normally expressed in the intestine, blood-brain barrier, kidney, liver, testes, placenta and in healthy haematopoietic stem cells, pgp is also expressed by approximately 35% of AML cases under 60 years of age and approximately 70% of elderly patients. 1 It is rarely expressed in children. Numerous studies have shown that pgp is a major predictor of chemoresistant disease in AML. 2 For example, studying 204 consecutive cases, Del Poeta et al 3 found a 40% CR rate in pgp-positive AML vs 72% in pgp-negative AML.
Pgp is responsible for the transport of a broad range of substrates across cell membranes, and is thus implicated in the efflux of chemotherapeutic drugs used in the treatment of AML, notably anthracyclines and etoposide. However, although pgp is commonly thought of as a drug efflux pump, we and others have shown that pgp has functions independent of its role in drug efflux, particularly as an antiapoptotic molecule. 2 In primary AML cells, we have found strong evidence that the major function of pgp is as a prosurvival molecule rather than as an inhibitor of drug-induced killing. 4 Other groups have also noted a drug-efflux independent role for pgp in promoting tumour cell survival. 5, 6 Moreover, inhibition of fas-induced apoptosis by pgp has been noted in several studies. [7] [8] [9] The proposed mechanisms by which pgp promotes cell survival include modulation of ion pump activity and of endogenous substrate translocation. Direct evidence of pgp-protein interactions underlying these activities has not been found, but pgp-lipid interactions may account for the broad range of effects. The lipid composition of cancer cell membranes tends to differ from that of healthy cell counterparts. Notably, cholesterol and sphingolipid concentrations can be elevated, and this is particularly true of multidrug-resistant (MDR) cells. 10 Pgp is well established as a broad-specificity lipid translocator. It is thought to affect apoptosis through multiple effects on the ceramide pathway including modulation of sphingomyelin transbilayer movement, glucosylceramide transport and lactosylceramide formation. [11] [12] [13] Pgp may also play an active role in stabilising cholesterol-rich rafts and caveolae by relocating cholesterol from the cytosolic to exoplasmic leaflet of the plasma membrane. 14 Ceramide has been demonstrated to have a key role in activating cell death initiated by cytotoxic drugs (see Figure 1) . Cabot et al 15 have previously shown that a decrease in intracellular ceramide levels is found in the MCF-7-ADR drugresistant breast cancer cell line. In this cell line, there is increased activity of the ceramide-metabolising enzyme glucosylceramide synthase (GCS), which metabolises ceramide to glucosylceramide. High levels of GCS activity and sphingomyelin synthase activity have recently been associated with low intracellular ceramide levels and with a drug-resistant phenotype in AML. 16 Our recent research in this area has focused on the pathway through which proapoptotic ceramide might be diminished from the signalling pool by its metabolism to glucosylceramide and the role of pgp in this process. It has been proposed that the lipid glucosylceramide is translocated by pgp at the Golgi, leading to reduced levels of ceramide on the cytoplasmic side and enhanced levels of glucosylceramide metabolites on the lumenal side (see Figure 1) . 12, 17 Using pgp-positive TF-1 cells, we have shown that pgp is present in the Golgi of AML cells, that glucosylceramide is a pgp substrate and that GCS activity is inhibited by the pgp inhibitors cyclosporin and GF120918. 18 These results indicate that pgp is involved in depleting cytosolic levels of glucosylceramide through its role as a lipid transporter, hence leading to increased GCS activity, decreased intracellular levels of ceramide and a drug-resistant phenotype. Similar findings have been made in breast cancer cells. 17 Although resistance to chemotherapy already exists prior to the initiation of therapy as manifest by the expression of pgp by AML blasts at diagnosis, drug resistance may also be acquired or inducible as part of a cellular response to cytotoxic therapy. Recently, the mechanisms underlying inducible resistance have been explored. One pathway involves the transcription factor NF-kB, which has been found to be constitutively activated in AML, 19 and expression of which is further upregulated in response to anthracycline exposure, presumably as part of a cell survival pathway to limit the toxic effects of the drug. 20 NFkB activation induces the expression of a number of genes involved in apoptosis resistance, including IAP-1 and -2, which block the activation of caspase 8. 21 Inhibition of NF-kB activation with a proteasome inhibitor has been reported to enhance anthracycline-induced apoptosis and represents a target for overcoming inducible drug resistance in AML blasts. 22 Another pathway activated following anthracycline exposure in AML cells, and which has been shown to contribute to cell survival signals, involves the MAPK pathway and PKC zeta. Mansat-De Mas et al 23 have shown that daunorubicin treatment of U937 cells increased phosphorylation of extracellular-regulated kinases (ERKs) and stimulated activation of raf1 and ERK1, leading to an increase in PKC zeta activity. Inhibition of PKC zeta resulted in an increase in daunorubicin-induced apoptosis, suggesting that pharmacologic manipulation of this pathway of inducible drug resistance may enhance daunorubicin cytotoxicity.
Review of the current status of trials using pgp modulation
Pgp is the best-characterised drug resistance molecule in AML. Consequently, various attempts have been made to circumvent the adverse outcome associated with pgp expression by using drug efflux modulators such as quinine, cyclosporin and its analogue PSC 833. These studies have been complicated by the effect of cyclosporin and PSC833 (but not quinine) on the pharmacokinetics of cytotoxic drugs, which have necessitated dose reductions of anthracyclines in some of these trials.
Variable and inconsistent clinical results have been reported. In the first GOELAMS trial in which 315 patients with high-risk AML receiving mitoxantrone and Ara-C were randomised to receive quinine, there was a nonsignificant increase in CR rate from 45 to 53% (P ¼ 0.19), but a significant reduction in resistant disease from 40 to 28% (P ¼ 0.04) in the quinine arm. 24 In a second GOELAMS/GFM trial in high-risk MDS, quinine was shown to increase the CR rate from 18 to 52% (P ¼ 0.02) and the median survival from 8 to 13 months (P ¼ 0.01) of pgp-positive patients treated with mitoxantrone and high-dose AraC, but to have no impact in pgp-negative disease. 25 In a recent GOELAMS study in de novo AML patients between 15 and 60 years, the addition of quinine to induction therapy with idarubicin and AraC had no effect on the overall CR rate or survival, perhaps because the majority (70%) of patients were pgp negative. However, in the subgroup of patients defined as pgp positive by having functional rhodamine efflux, the CR rate was improved from 48 to 82.8% (P ¼ 0.01) and the median survival from 12 to 24 months, although this was not statistically different. 26 The greatest success for the strategy of pgp reversal was seen in the SWOG study where patients with relapsed or refractory AML were randomised to receive cyclosporin in addition to daunorubicin and AraC for induction and consolidation. 27 In this study, which used infusional rather than bolus dose daunorubicin, the CR rate was not significantly improved in the cyclosporin arm (45 vs 36%, P ¼ 0.065), although the frequency of resistant disease was reduced (47 vs 31%, P ¼ 0.0077). However, both relapse-free survival (34 vs 9%, P ¼ 0.031) and overall survival (22 vs 12%, P ¼ 0.046) at 2 years were significantly improved. Furthermore, this benefit was particularly seen in the group of patients with moderate/high pgp expression (defined using the MRK16 antibody), where the median survival was increased from 4 to 12 months, whereas there was no benefit in patients with low or absent pgp expression. These positive results contrast with those reported in an MRC study in a similar patient group where the addition of cyclosporin to bolus dose daunorubicin, AraC and etoposide (ADE) had no impact on either CR rate or survival. 28 The major differences between these two studies were the mode of delivery of daunorubicin as a 72 h infusion and the significantly higher doses of cyclosporin used by the SWOG group, which resulted in the achievement of blood cyclosporin levels capable of inhibiting pgp function.
PSC 833 is a more potent and specific pgp inhibitor than cyclosporin. However, a number of randomised trials have not demonstrated any benefit for this agent in AML, primarily due to excess toxicity. A CALGB study of PSC 833 combined with ADE in patients with AML 460 years was prematurely discontinued because of excess early mortality in the group receiving PSC 833. 29 The excess toxicity appeared to be mainly nonhaematological, despite a lower dose of daunorubicin in the PSC arm. Furthermore, the UK MRC AML14 trial in which patients 460 years were randomised to receive daunorubicin and AraC7PSC 833 also had a significantly higher incidence of induction deaths (Burnett et al, in preparation). Also, an ECOG study for relapsed/ refractory AML, which compared mitoxantrone, etoposide and Ara-C with or without PSC 833, showed no benefit in the PSC 833 arm. 30 Overall, the clinical studies of Pgp modulation have provided conflicting and potentially confusing messages. Only one study, the SWOG study using cyclosporin combined with infusional daunorubicin and Ara C, has shown an overall survival advantage. However, the GOELAMS studies which used quinine have shown an evidence of a response in patients with Figure 1 Ceramide has a key role in activating cell death initiated by cytotoxic drugs. The proapoptotic lipid ceramide can be formed through multiple pathways, notably by sphingomyelin hydrolysis at the plasma membrane and by de novo synthesis. Both of these pathways can be stimulated by cytotoxic drugs such as daunorubicin. Ceramide is metabolised by GCS to glucosylceramide on the cytoplasmic side of the Golgi, whereupon glucosylceramide is translocated to the luminal side and further metabolised. Glucosylceramide is overexpressed in drug-resistant AML cells. pgp can mediate the translocation of both sphingomyelin and glucosylceramide across cell membranes and is hypothesised to thus affect the rate of ceramide formation and metabolism. Pgp inhibitors such as cyclosporin and verapamil, as well as glucosylceramide synthase inhibitors such as PPMP, inhibit the rate of GCS in intact cells. However, our own data, using the pgp inhibitors cyclosporin and GF120918, show that this inhibition does not occur in cell-free assays, thus supporting the concept that a feature of intact cells, such as transport across membranes, is the target of the inhibition.
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M Pallis and N Russell pgp-positive AML. The disappointing results seen with PSC 833 compared to cyclosporin and quinine may be explained by the significant anthracycline dose reductions of between 30 and 50%, which were made in order to allow for the altered pharmacokinetics induced by the PSC 833. These differences do, however, raise the question of the mode of action of these agents. Could non-drug-efflux mechanisms of action also be relevant? Cyclosporin has indirect inhibitory activity against GCS, increased activity of which has been associated with a multidrug resistance phenotype. 31 We believe that the mode of action of cyclosporin in this context results from inhibiting the pgp-dependent translocation of glucosylceramide (Figure 1) , because cyclosporin only inhibits GCS activity in intact AML cells (membrane transporters operative) but not in a cell lysate (no transport function required). 18 Inhibition of GCS enhances intracellular levels of the proapoptotic mediator ceramide, which has a key role as a mediator of daunorubicin-induced apoptosis. PSC833 has a different effect, raising ceramide levels by stimulating de novo synthesis. 32 Cyclosporin also inhibits the activity of the NF-kB transcription factor. 33 NF-kB has been shown to upregulate Pgp expression, and has also been demonstrated to be an important mediator of inducible drug resistance in AML cells. It is therefore plausible that the ability of cyclosporin to interact with other pathways which can lead to multidrug resistance may contribute to the contrasting results seen between cyclosporin and PSC 833 in clinical trials.
Is the further evaluation of pgp inhibitors in AML justified? The promising results with cyclosporin and with quinine, which does not affect anthracycline pharmacokinetics, certainly supports this approach. Third-generation pgp inhibitors such as VX-710 (biricodar) and zosuquidar are now entering clinical trials. These molecules have the advantage of not affecting anthracycline pharmacokinetics, and are also available orally. Further studies of these agents are required in AML; however, we feel that these trials should be confined to patients established as being pgp positive prior to starting therapy. The inclusion of analysis of pgp expression in routine haematopathology laboratories as part of the diagnostic work-up of AML should be feasible given our ability to standardise the methodology. [34] [35] [36] Are there alternative strategies to overcoming multidrug resistance in AML?
An alternative strategy to circumvent pgp-mediated drug resistance is to use a combination of drugs that are not effluxed by this pathway: such drugs include AraC and idarubicin. The combination of fludarabine, AraC (FLAG)7Idarubicin has been widely used in resistant or relapsed AML although studies as first-line treatment are rare. We have previously observed a high CR rate in response to FLAG in pgp-positive AML cases with primary resistance to DAT. 37 Furthermore, when using a flow cytometric assay of cell survival, we observed that in vitro responses to FLAG differed from DAT, depending upon pgp status. Pgp-positive AML blasts were more sensitive to the combination of fludarabine/AraC than to daunorubicin/AraC. Conversely, pgp-negative blasts were more sensitive to daunorubicin/AraC. 38 The efficacy of FLAG plus idarubicin compared to DA is being studied in the current MRC AML15 trial, which includes measurements of multidrug resistance proteins. This trial also incorporates the use of the anti-CD33 antibodycalcheamicin conjugate (gemtuzamab ozogamicin). However, recently, pgp expression has been shown to be associated with a reduced in vivo response to this antibody and a reduced in vitro susceptibility to induction of apoptosis. 39 These results suggest that pgp is important in mediating clinical resistance to gemtuzanamb and that studies combined with pgp inhibitors are warranted.
Statins may also have activity against multidrug-resistant AML cells. Statins have been shown to decrease viability and induce apoptosis of both AML cell lines and primary AML cells, with little or no activity against normal haemopoietic progenitors. 40, 41 Statins inhibit the enzyme HMG-CoA reductase, which is a rate limiting enzyme in the mevalonate pathway which leads to the synthesis of cholesterol. AML cells upregulate cholesterol synthesis in response to cytotoxic drug exposure and it has been proposed that higher cellular cholesterol levels may improve leukaemia cell survival and impart relative resistance to therapy. 42 This mechanism is particularly interesting because of the potential to modulate cholesterol synthesis in vivo using cholesterol-lowering agents. Pgp-expressing AML cells have higher levels of HMG-CoA reductase and are more sensitive to the growth-inhibitory effect of statins than their parental cell lines. 43 Pgp is predominately localised within cholesterol-rich plasma membrane microdomains, which are disrupted by cholesterol depletion. 44, 45 This suggests that statins and other inhibitors of the cholesterol biosynthetic pathway may be of value in modulating pgp-mediated drug resistance in AML.
Of course, there are multiple other mechanisms of cellular drug resistance in AML apart from pgp. These include the expression of other drug efflux pumps, including MRP1, MRP3, LRP and BCRP. The expression of antiapoptotic proteins including bcl2 and bcl-x, and the ratio between bax and bcl2 have all been reported to affect response to treatment in AML. It is therefore likely that future studies may have to be more targeted in their approach reflecting the established heterogeneity of drug resistance pathways existing in this disease.
